Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Sandmann S, Unger T
L- and T-type calcium channel blockade - the efficacy of the calcium channel antagonist mibefradil
Journal of Clinical and Basic Cardiology 1999; 2 (2): 187-201

PDF    Summary    Overview   

First Image Fig. 4: Kalziumkanal - Mibefradil Fig. 5: Kalziumkanal - Mibefradil Fig. 6: Kalziumkanal - Mibefradil This Image - Fig. 7: Kalziumkanal - Mibefradil Fig. 8A-B: Kalziumkanal - Mibefradil Fig. 9: Kalziumkanal - Mibefradil Fig. 10: Kalziumkanal - Mibefradil Last Image
Figure/Graphic 7: Kalziumkanal - Mibefradil
Effects of verapamil (1 mg/kg i.v.) and mibefradil (3 mg/kg i.v.) on coronary blood flow (CBF) in dogs compared to placebo treated controls. CBF was measured with radioactive microspheres before and 10 min after initiation of drug treatment. Mean +/- SEM, * p<0.05 versus before therapy
 
Kalziumkanal - Mibefradil
Previous Image Next Image   


Figure/Graphic 7: Kalziumkanal - Mibefradil
Effects of verapamil (1 mg/kg i.v.) and mibefradil (3 mg/kg i.v.) on coronary blood flow (CBF) in dogs compared to placebo treated controls. CBF was measured with radioactive microspheres before and 10 min after initiation of drug treatment. Mean +/- SEM, * p<0.05 versus before therapy
 
copyright © 2000–2025 Krause & Pachernegg GmbH | Sitemap | Datenschutz | Impressum
 
Werbung